In This Issue/Research Watch/News-in-Brief/News from the IASLC Tobacco Control Committee
Checkpoint Inhibitors in Lung Cancer Are Not Immune from Cost-Effectiveness Analysis
Trimodality Approach to Stage IIIA-N2 NSCLC: As Good as It Gets?
Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC
Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing
Perceptions and Utilization of Lung Cancer Screening Among Primary Care Physicians
A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana’s Platform
Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment
Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma
Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma
EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma
Silencing NKD2 by Promoter Region Hypermethylation Promotes Esophageal Cancer Progression by Activating Wnt Signaling
Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1 Antibodies
Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection
Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
Comprehensive Clinical Staging for Resectable Lung Cancer: Clinicopathological Correlations and the Role of Brain MRI
The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma
Anatomical Segmentectomy and Wedge Resections Are Associated with Comparable Outcomes for Patients with Small cT1N0 Non–Small Cell Lung Cancer
Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD-L1 Antibody Avelumab
BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study
A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207
Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies
Clinical Activity of Alectinib in Advanced RET -Rearranged Non–Small Cell Lung Cancer
A 65-Year-Old Patient with Superior Vena Cava Syndrome and Bone Metastases
Occam’s Razor and Hickam’s Dictum: A Rare Case of Synchronous Solid and Hematological Malignancies and Transformed EGFR -Mutated NSCLC
Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-Review
BRCA1-Associated Protein 1 Testing in Cancer
Expanding Tumor Lymphocytic Infiltration as a Prognostic Tool to Patients with NSCLC Who Are Treated with Radiotherapy?
PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?
Adjuvant Chemotherapy, Retrospective Cohorts, and the Immortal Time Bias
It’s All in the “Swerve of the Curve”